Otoimmün Epilepsiler
Özet
Otoimmün epilepsiler, dünya nüfusunun yaklaşık %1'ini etkileyen epilepsi vakaları içinde önemli bir yer tutan ve International League Against Epilepsy (ILAE) tarafından ayrı bir klinik antite olarak kabul edilen hastalıklardır. Genellikle akut veya subakut ilerleme gösteren bu rahatsızlıkta, hastalar sıklıkla standart antiepileptik ilaçlara dirençli nöbetlerle başvururlar. Tanı süreçleri; detaylı klinik değerlendirme, beyin MR görüntülemesi, elektroensefalogram (EEG) bulguları ve beyin omurilik sıvısı (BOS) analizlerine dayanmaktadır. Bu kapsamda geliştirilen APE2 skoru, klinisyenlere nöral spesifik antikor seropozitifliğini ve otoimmün etiyolojiyi tahmin etmede yüksek duyarlılık ve özgüllük sunan önemli bir kılavuzdur. Hastalıkta rol oynayan otoantikorlar, NMDA-R ve LGI1 gibi hücre yüzey epitopları ile GAD65 ve anti-Hu gibi hücre içi epitoplar olmak üzere iki ana grupta incelenmektedir. Klinik gidişatı doğrudan etkileyen en kritik faktör, immünolojik tetikleyicilerin (maligniteler veya enfeksiyonlar) hızlıca tespiti ve erken dönemde immünoterapiye başlanmasıdır. Akut fazda yüksek doz metilprednizolon, IVIG veya plazma değişimi tercih edilirken; dirençli veya tekrarlayan vakalarda rituksimab gibi ajanlarla idame tedavisi uygulanarak nöbet sıklığının azaltılması ve kognitif fonksiyonların korunması hedeflenir.
Autoimmune epilepsies represent a distinct clinical entity within epilepsy cases—which affect approximately 1% of the global population—and are formally recognized as such by the International League Against Epilepsy (ILAE). Characterized by an acute or subacute progression, these conditions typically manifest as seizures that remain highly refractory to standard antiepileptic medications. The diagnostic workflow relies heavily on clinical evaluation, brain MRI, electroencephalogram (EEG) findings, and cerebrospinal fluid (CSF) analysis. In this regard, the APE2 scoring system serves as a pivotal guide for clinicians, predicting neural-specific antibody seropositivity and autoimmune etiology with high sensitivity and specificity. The pathogenic autoantibodies involved are categorized into cell-surface epitopes, such as NMDA-R and LGI1, and intracellular epitopes, including GAD65 and anti-Hu. The most critical determinant of the clinical outcome is the prompt identification of underlying immunological triggers, such as occult malignancies or infections, combined with the early initiation of immunotherapy. Acute management leverages high-dose methylprednisolone, IVIG, or plasma exchange, whereas maintenance regimens utilize agents like rituximab for refractory cases to optimize seizure control and preserve cognitive faculties.
Referanslar
Ong MS, Kohane IS, Cai T, et al. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014;71(5): 569-574. doi: 10.1001/jamaneurol.2014.188
Dubey D, Pittock SJ, McKeon A. Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. Epilepsia. 2019;60(2): 367-369. doi: 10.1111/epi.14649
Dubey D, Alqallaf A, Hays R, et al. Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology. JAMA Neurol. 2017;74(4): 397-402. doi: 10.1001/jamaneurol.2016.5429
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4): 512-521. doi: 10.1111/epi.13709
Britton J. Autoimmune epilepsy. Handb Clin Neurol. 2016;133: 219-45. doi: 10.1016/b978-0-444-63432-0.00013-x
Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med. 2018;378(9): 840-851. doi: 10.1056/NEJMra1708712
Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014;82(18): 1578-1586. doi: 10.1212/wnl.0000000000000383
Dubey D, Pittock SJ, Kelly CR, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1): 166-177. doi: 10.1002/ana.25131
Dubey D, Singh J, Britton JW, et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia. 2017;58(7): 1181-1189. doi: 10.1111/epi.13797
Abramovici S, Bagić A. Epidemiology of epilepsy. Handb Clin Neurol. 2016;138: 159-171. doi: 10.1016/b978-0-12-802973-2.00010-0.
Husari KS, Dubey D. Autoimmune Epilepsy. Neurotherapeutics. 2019;16(3): 685-702. doi: 10.1007/s13311-019-00750-3
Bauer J, Becker AJ, Elyaman W, et al. Innate and adaptive immunity in human epilepsies. Epilepsia. 2017;58 Suppl 3(Suppl Suppl 3): 57-68. doi: 10.1111/epi.13784
Fujinami RS, von Herrath MG, Christen U, et al. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1): 80-94. doi: 10.1128/cmr.19.1.80-94.2006
Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17(9): 760-772. doi: 10.1016/s1474-4422(18)30244-8
Jang Y, Kim DW, Yang KI, et al. Clinical Approach to Autoimmune Epilepsy. J Clin Neurol. 2020;16(4): 519-529. doi: 10.3988/jcn.2020.16.4.519
Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13(2): 167-77. doi: 10.1016/s1474-4422(13)70282-5
Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Ann Neurol. 2017;81(2): 298-309. doi: 10.1002/ana.24881
Dubey D, Kothapalli N, McKeon A, et al. Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. J Neuroimmunol. 2018;323:62-72. doi: 10.1016/j.jneuroim.2018.07.009
Spatola M, Dalmau J. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. Curr Opin Neurol. 2017;30(3): 345-353. doi: 10.1097/wco.0000000000000449
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2): 157-65. doi: 10.1016/s1474-4422(12)70310-1
Dalmau J, Geis C, Graus F. Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. Physiol Rev. 2017;97(2): 839-887. doi: 10.1152/physrev.00010.2016
Quek AML, O'Toole O. Autoimmune Epilepsy: The Evolving Science of Neural Autoimmunity and Its Impact on Epilepsy Management. Semin Neurol. 2018;38(3): 290-302. doi: 10.1055/s-0038-1660860
López-Chiriboga AS, Klein C, Zekeridou A, et al. LGI1 and CASPR2 neurological autoimmunity in children. Ann Neurol. 2018;84(3): 473-480. doi: 10.1002/ana.25310
Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5): 892-900. doi: 10.1002/ana.22307
Gadoth A, Pittock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol. 2017;82(1): 79-92. doi: 10.1002/ana.24979
Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65(4): 424-434. doi: 10.1002/ana.21589
Haselmann H, Mannara F, Werner C, et al. Human Autoantibodies against the AMPA Receptor Subunit GluA2 Induce Receptor Reorganization and Memory Dysfunction. Neuron. 2018;100(1):91-105.e9. doi: 10.1016/j.neuron.2018.07.048
Höftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. Neurology. 2015;84(24): 2403-2412. doi: 10.1212/wnl.0000000000001682
Joubert B, Kerschen P, Zekeridou A, et al. Clinical Spectrum of Encephalitis Associated With Antibodies Against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor: Case Series and Review of the Literature. JAMA Neurol. 2015;72(10): 1163-1169. doi: 10.1001/jamaneurol.2015.1715
Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73(1): 120-128. (In eng). doi: 10.1002/ana.23756
Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77(18): 1698-1701. doi: 10.1212/WNL.0b013e3182364a44
Spatola M, Sabater L, Planagumà J, et al. Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. Neurology. 2018;90(22): e1964-e1972. doi: 10.1212/wnl.0000000000005614
Pittock SJ, Yoshikawa H, Ahlskog JE, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006;81(9): 1207-1214. doi: 10.4065/81.9.1207
Peltola J, Kulmala P, Isojärvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology. 2000;55(1): 46-50. doi: 10.1212/wnl.55.1.46
Lilleker JB, Biswas V, Mohanraj R. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure. 2014;23(8): 598-602. doi: 10.1016/j.seizure.2014.04.009.
Larman HB, Zhao Z, Laserson U, et al. Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 2011;29(6): 535-541. doi: 10.1038/nbt.1856
Scharf M, Miske R, Kade S, et al. A Spectrum of Neural Autoantigens, Newly Identified by Histo-Immunoprecipitation, Mass Spectrometry, and Recombinant Cell-Based Indirect Immunofluorescence. Front Immunol. 2018;9: 1447. doi: 10.3389/fimmu.2018.01447
Sun H, Chen GY, Yao SQ. Recent advances in microarray technologies for proteomics. Chem Biol. 2013;20(5): 685-699. doi: 10.1016/j.chembiol.2013.04.009.
Roberts WK, Deluca IJ, Thomas A, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest. 2009;119(7): 2042-2051. doi: 10.1172/jci36131
Dubey D, Toledano M, McKeon A. Clinical presentation of autoimmune and viral encephalitides. Curr Opin Crit Care. 2018;24(2): 80-90. doi: 10.1097/mcc.0000000000000483
Rudzinski LA, Pittock SJ, McKeon A, et al. Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis. Epilepsy Res. 2011;95(3): 255-262. doi: 10.1016/j.eplepsyres.2011.04.006
Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53(5): 580-587. doi: 10.1002/ana.10518
Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(Pt 8): 1831-1844. doi: 10.1093/brain/awh203
Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999;340(23): 1788-1795. doi: 10.1056/nejm199906103402303
Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2): 146-154.
Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128(Pt 3): 454-471. doi: 10.1093/brain/awh415
Longaretti F, Dunkley C, Varadkar S, et al. Evolution of the EEG in children with Rasmussen's syndrome. Epilepsia. 2012;53(9): 1539-1545. doi: 10.1111/j.1528-1167.2012.03565.x
Vining EP, Freeman JM, Pillas DJ, et al. Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996. Pediatrics. 1997;100(2 Pt 1): 163-171. doi: 10.1542/peds.100.2.163
Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology. 2015;85(18): 1604-1613. doi: 10.1212/wnl.0000000000001940
Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia. 2018;59(4): 745-752. doi: 10.1111/epi.14022
Baykan B, Gungor Tuncer O, Vanli-Yavuz EN, et al. Delta Brush Pattern Is Not Unique to NMDAR Encephalitis: Evaluation of Two Independent Long-Term EEG Cohorts. Clin EEG Neurosci. 2018;49(4): 278-284. doi: 10.1177/1550059417693168
Schmitt SE, Pargeon K, Frechette ES, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11): 1094-1100. doi: 10.1212/WNL.0b013e3182698cd8
Aurangzeb S, Symmonds M, Knight RK, Kennett R, Wehner T, Irani SR. LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures. Seizure. 2017;50: 14-17. doi: 10.1016/j.seizure.2017.05.017
Escudero D, Guasp M, Ariño H, et al. Antibody-associated CNS syndromes without signs of inflammation in the elderly. Neurology. 2017;89(14): 1471-1475. doi: 10.1212/wnl.0000000000004541
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4): 391-404. doi: 10.1016/s1474-4422(15)00401-9
Ohta K, Seki M, Dalmau J, Shinohara Y. Perfusion IMP-SPECT shows reversible abnormalities in GABA(B) receptor antibody associated encephalitis with normal MRI. Brain Behav. 2011;1(2): 70-72. doi: 10.1002/brb3.14
Guerin J, Watson RE, Carr CM, et al. Autoimmune epilepsy: findings on MRI and FDG-PET. Br J Radiol. 2019;92(1093): 20170869. doi: 10.1259/bjr.20170869
Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8): 1135-1140. doi: 10.1136/jnnp.2003.034447
Pittock SJ, Palace J. Paraneoplastic and idiopathic autoimmune neurologic disorders: approach to diagnosis and treatment. Handb Clin Neurol. 2016;133:165-183. doi: 10.1016/b978-0-444-63432-0.00010-4
Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136(Pt 10): 3151-3162. doi: 10.1093/brain/awt212
Carreño M, Bien CG, Asadi-Pooya AA, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017;129: 101-105. doi: 10.1016/j.eplepsyres.2016.12.010
Malter MP, Frisch C, Zeitler H, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015;30: 57-63. doi: 10.1016/j.seizure.2015.05.017
